Evidence map›Paper›PMID 34611395›Full record

ArticleDrug design, development and therapy2021

The Synergistic Effects of

Yun Zhang, Jie Wang, Yong-Mei Liu, Yin-Ying Chen, Xiao-Chen Yang, Lian Duan

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Cardiovascular Benefits ofFood science & nutrition · 2026
    Review
  2. Frontiers in pharmacology · 2025
    Review
  3. Experimental and therapeutic medicine · 2023
    Review
  4. Article
  5. Mechanism of Action of Flavonoids ofMolecules (Basel, Switzerland) · 2022
    Article
  6. Frontiers in pharmacology · 2022
    Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yun ZhangDepartment of Immunology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People's Republic of China.ORCID 0000-0003-3176-3142
Jie WangDepartment of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People's Republic of China.
Yong-Mei LiuDepartment of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People's Republic of China.
Yin-Ying ChenDepartment of the Scientific Research Office, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People's Republic of China.
Xiao-Chen YangDepartment of Cardiology & Health Care, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People's Republic of China.
Lian DuanDepartment of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People's Republic of China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeTwo Chinese herbal medicines Huang Qi (HQ,

methodsThe active components and targets of HQ and DS, CHD-related genes, and the biological progression were analysed by network pharmacology. The myocardial infarction (MI) rat model was established by ligating the left anterior descending coronary artery. Cardiac function was detected by ultrasonic electrocardiography. The MI size, fibrosis, cardiac hypertrophy, lipid metabolism, blood viscosity, and coagulation indexes were analysed by histological staining or chemical methods, respectively.

resultsA total of 170 shared and specific seed genes of HQ and DS against CHD were identified. The shared and specific biological processes of HQ and DS against CHD were obtained. The LVEF and LVFS values significantly increased, the myocardium infarct size and fibrosis significantly decreased, the values of lipid metabolism indexes and blood viscosity indexes significantly reduced in the HQ + DS treatment group vs HQ or DS single treatment (

conclusionIn MI rats, HQ and DS exhibited synergistic effects on improving cardiac function, reducing MI size, fibrosis, regulating hyperlipidaemia, and maintaining circulatory system homeostasis; HQ had the specific advantage of alleviating cardiac remodelling; DS had the specific advantage of regulating hypercoagulability. This study revealed that HQ and DS not only exerted synergistic effects but also exhibited complementary effects on CHD.

Indexed as

AnimalsAstragalus propinquusCoronary DiseaseDisease Models, AnimalDrugs, Chinese HerbalDrug SynergismMaleMyocardial InfarctionNetwork PharmacologyRatsRats, Sprague-DawleySalvia miltiorrhizaStroke VolumeVentricular Function, Leftdan-shen root extractDrugs, Chinese HerbalHuang QiAstragalus mongholicuscoronary heart diseasemyocardial infarctionnetwork pharmacologySalvia miltiorrhizasynergistic effects

Identifiers

PMID34611395
PMCPMC8486279
OpenAlexW3203200102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.